The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
Susan Haigney
Advertisement
Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.
Articles by Susan Haigney
CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.
Advertisement
Latest Updated Articles
- Growth in Biologics Market Inspires Outsourcing
February 1st 2020
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
5